LN PHARMA CONSULTING

Active

Private limited companyfounded 20206 yrs activeRue Toute-Voie 12, 4101 Seraing, BelgiumKBO/BCE: BE 0751.561.740

Summary

The computed 12-month bankruptcy probability of LN PHARMA CONSULTING is 1.7% (moderate). The 2025 annual accounts show equity of €12k and a net result of €52k. Equity is shrinking by ~36% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2027. Its solvency ranks better than 31% of 18280 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

Score 2025

61 / 100

Healthy

The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability100=

Solvency37▲+2

Growth58=

Track record100

Bankruptcy probability, 12 months

1.7% Moderate

0%0.5%1.5%4%10%≥ 25%

Credit up to €500 at 30 days acceptable

Liquidity tight (current ratio 1.12 against 1.12 in 2024; short-term debt: 87.8% and cash: 38.8% of total assets), and 87.8% of the assets are financed with debt.

How do we compute the score and the probability?

Credit check for your own amount and term

Signals

Six signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Limited track record

This company has not been active as long as an established one and statistically fails somewhat more often.

KBO · incorporation date

Age against the risk zone

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 47

Relative position

BE, all sectors

reference

Sector 47

higher

← fewer bankruptcies more bankruptcies →

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

12.2%

Return on assets

55.5%

Age of the figures

9 mo

Higher-failure-rate region

In this region companies fail more often than in the rest of the country.

KBO · registered office

Growing equity

Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.

NBB · annual accounts 2025

Equity per financial year

2122232425

2021 to 2025 · latest year €12k

Filed after the deadline

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.

NBB · 5 filings

Deviation from the deadline

2025

27 d late

2024

110 d late

2023

33 d early

2022

31 d early

2021

2 d early

← before the deadline after the deadline →

Checked, nothing found (2)

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

24-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Equity

€12k▲ 25.3%

2024 · €9k

2021: €25k 2022: €19k 2023: €10k 2024: €9k

2021 → 2025

Total assets

€94k▲ 7.6%

2024 · €88k

2021: €49k 2022: €20k 2023: €53k 2024: €88k

2021 → 2025

Net result

€52k▲ 6.1%

2024 · €49k

2021: €20k 2022: €-6k 2023: €26k 2024: €49k

2021 → 2025

Working capital

€10k▲ 11.8%

2024 · €9k

2021: €24k 2022: €19k 2023: €10k 2024: €9k

2021 → 2025

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line20212022202320242025Trend

Equity€25k-€19k▼ 24.0%€10k▼ 48.2%€9k▼ 6.8%€12k▲ 25.3%

Operating result€26k-€-5k€30k€62k▲ 104%€62k▼ 0.2%

Net result€20k-€-6k€26k€49k▲ 90.8%€52k▲ 6.1%

Turnover and EBIT margin not published: the micro schema does not require them.

Result per fiscal year

Operating resultNet result

The operating result falls in 2025; 2025 is 0% below 2024.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €94k

98.7%

Fixed assets €1k

Current assets €93k

Equity and liabilities €94k

12.2%

87.8%

Equity €12k ▲ 25.3%

Debt €83k ▲ 5.5%

Debt's share of the balance-sheet total falls from 89.5% to 87.8%. Equity and debt are higher.

Key figures and ratios

2025 value · change against 2024

EBITDA

€62k

Cash flow

€52k

Current ratio

1.12▲

2024 · 1.12

Debt to equity

7.19▼

2024 · 8.54

ROE

455.0%▼

2024 · 537.6%

ROA

55.5%▼

2024 · 56.3%

Interest coverage

1442.53

Debt ≤ 1 year

€83k▲

2024 · €78k

Income taxes

€15k▼

2024 · €16k

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Filed annual accounts As filed with the NBB · 2025 against 2024 · 37 lines

Balance sheet Code20242025

Assets

Total assets20/58€88k€94k▲

Fixed assets21/28-€1k

Tangible fixed assets22/27-€1k

Furniture and vehicles24-€1k

Current assets29/58€88k€93k▲

Amounts receivable within one year40/41€62k€56k▼

Trade receivables40-€14k

Other amounts receivable41€62k€42k▼

Cash at bank and in hand54/58€15k€37k▲

Deferred charges and accrued income490/1€10k€627▼

Equity and liabilities

Total equity and liabilities10/49€88k€94k▲

Equity10/15€9k€12k▲

Contributions10/11€5k€5k=

Profit (loss) carried forward14€4k€7k▲

Amounts payable17/49€78k€83k▲

Amounts payable within one year42/48€78k€83k▲

Trade debts44€1k€614▼

Suppliers440/4€1k€614▼

Taxes, remuneration and social security45€77k€82k▲

Taxes450/3€27k€41k▲

Remuneration and social security454/9€50k€41k▼

Income statement Code20242025

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630-€126

Other operating charges640/8€2k€690▼

Gross operating margin9900€64k€63k▼

Operating profit (loss)9901€62k€62k▼

Financial income75/76B€3k€5k▲

Recurring financial income75€3k€5k▲

Financial charges65/66B€330€43▼

Recurring financial charges65€330€43▼

Profit (loss) for the period before taxes9903€65k€67k▲

Income taxes67/77€16k€15k▼

Profit (loss) for the period9904€49k€52k▲

Profit (loss) for the period to be appropriated9905€49k€52k▲

Appropriation of the result

Profit (loss) to be appropriated9906€54k€57k▲

Profit (loss) brought forward from the previous period14P€5k€4k▼

Profit to be distributed694/7€50k€50k=

Return on contributions (dividend)694€50k€50k=

The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 9Financial 4Filings 5

Next filing, fiscal year 2026, expected by 31-07-2027

2026

27-08

NBB filing Annual accounts filed

fiscal year 2025 · micro schema · 27 days late

2025

31-12

Financial Highest result since 2021net €52k ▲6.1%

Net result €52k, the highest in the series.

18-11

NBB filing Annual accounts filed

fiscal year 2024 · micro schema · 110 days late

2024

28-06

NBB filing Annual accounts filed

fiscal year 2023 · micro schema

2023

31-12

Financial Back to profitnet €26k

Net result €26k after one loss-making year.

30-06

NBB filing Annual accounts filed

fiscal year 2022 · micro schema

2022

31-12

Financial Weakest financial yearnet €-6k ▼130%

Net result drops to €-6k, the lowest in the series; recovery starts the following year.

31-12

Financial Liquidity times 11current ratio 21.30

Current ratio from 2.00 to 21.30; short-term debt falls from €24k to €935.

29-07

NBB filing Annual accounts filed

fiscal year 2021 · micro schema

Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.

Location & real-estate footprint

Registered office, Seraing · 1 establishment unit since 2020

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Rue Toute-Voie 124101 Seraing

Ground area

595 m²

Building footprint

112 m²

Volume, LiDAR

618 m³

Parcel 62058A0246/00L000, Wallonia · tallest building 9.2 m, ±2 floors. Linked by address, not a title deed.

1 establishment unit

LN PHARMA CONSULTING

Rue Toute-Voie 12, 4101 SeraingActivities of head offices; management consultancy activities

since 20202.308.257.629

1 parcel

Wallonia 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
62058A0246/00L000	Wallonia	595 m²	1 · 112 m²	9.2 m · 2 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Similar companies · same sector, comparable size

PHARMACIE DES PAGODES

Lessines · Eq €11,436

APOTHEEK VAN CAUSBROECK

BE 0472.757.610

Dendermonde · Eq €11,578

Sint-Lambrechts-Woluwe · Eq €11,634

Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 918 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Company data · Crossroads Bank

Identification

Legal formPrivate limited company

Founded28-07-2020

Fiscal year end31-12

Activities, NACEBEL 2025

47730Retail sale of pharmaceutical products

70200Business and other management consultancy

73300Public relations and communication consultancy

Sources

Crossroads Bank for EnterprisesNational Bank · 5 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.